In this two-part series, In Vivo will explore why organ on chip technology exists, the factors driving and limiting their application in drug development, and how companies can benefit from using them.
The cost of developing and taking a new drug to market can range from a hair under a billion to almost $3bn, with a study from the London School of Economics giving an average of $1.3bn.
It also takes typically between 10 and 15 years. Imjudo (tremelimumab-actl) for example, was approved in October 2022 after nearly two decades of work by AstraZeneca PLC. (Also see...
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
